Royalty Pharma Statistics

Total Valuation

Royalty Pharma has a market cap or net worth of EUR 13.42 billion. The enterprise value is 22.41 billion.

Market Cap	13.42B
Enterprise Value	22.41B

Important Dates

The last earnings date was Wednesday, August 6, 2025.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	Aug 15, 2025

Share Statistics

Current Share Class	432.29M
Shares Outstanding	n/a
Shares Change (YoY)	-2.95%
Shares Change (QoQ)	-2.73%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	379.85M

Valuation Ratios

The trailing PE ratio is 15.44 and the forward PE ratio is 5.76.

PE Ratio	15.44
Forward PE	5.76
PS Ratio	6.84
PB Ratio	1.66
P/TBV Ratio	2.91
P/FCF Ratio	n/a
P/OCF Ratio	6.55
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	25.79
EV / Sales	11.39
EV / EBITDA	n/a
EV / EBIT	13.67
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.84.

Current Ratio	1.26
Quick Ratio	1.26
Debt / Equity	0.84
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	7.02

Financial Efficiency

Return on equity (ROE) is 17.29% and return on invested capital (ROIC) is 6.70%.

Return on Equity (ROE)	17.29%
Return on Assets (ROA)	6.49%
Return on Invested Capital (ROIC)	6.70%
Return on Capital Employed (ROCE)	10.92%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.07% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+32.07%
50-Day Moving Average	30.87
200-Day Moving Average	28.79
Relative Strength Index (RSI)	42.71
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.58

Income Statement

In the last 12 months, Royalty Pharma had revenue of EUR 1.96 billion and earned 869.15 million in profits. Earnings per share was 1.98.

Revenue	1.96B
Gross Profit	2.30B
Operating Income	1.59B
Pretax Income	1.42B
Net Income	869.15M
EBITDA	n/a
EBIT	1.59B
Earnings Per Share (EPS)	1.98

Full Income Statement

Balance Sheet

The company has 549.31 million in cash and 6.83 billion in debt, giving a net cash position of -6.28 billion.

Cash & Cash Equivalents	549.31M
Total Debt	6.83B
Net Cash	-6.28B
Net Cash Per Share	n/a
Equity (Book Value)	8.09B
Book Value Per Share	12.50
Working Capital	267.13M

Full Balance Sheet

Cash Flow

Operating Cash Flow	2.05B
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 117.12%, with operating and profit margins of 81.09% and 44.28%.

Gross Margin	117.12%
Operating Margin	81.09%
Pretax Margin	72.22%
Profit Margin	44.28%
EBITDA Margin	n/a
EBIT Margin	81.09%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.79, which amounts to a dividend yield of 2.48%.

Dividend Per Share	0.79
Dividend Yield	2.48%
Dividend Growth (YoY)	3.92%
Years of Dividend Growth	5
Payout Ratio	36.87%
Buyback Yield	2.95%
Shareholder Yield	5.43%
Earnings Yield	6.48%
FCF Yield	n/a

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Royalty Pharma has an Altman Z-Score of 1.54 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.54
Piotroski F-Score	6